Avastin.net

Efficacy across tumours

• Solid tumours are unable to grow beyond a size of 1–2mm, or undergo further growth and metastasis, without the ability to establish their own blood supply through angiogenesis^1–3
  • an anticancer agent such as Avastin that inhibits this process should, therefore, have activity against all types of solid tumours.⁴

• Within each tumour type, anti-angiogenic therapy should also benefit patients, regardless of demographics or disease characteristics.

• This section explores the clinical evidence supporting the above hypotheses.

Avastin has efficacy across tumour types
Why search for a biomarker for Avastin?
The search for a predictive biomarker for Avastin
All patient subgroups can benefit from Avastin